Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 171, Issue 1, 2015, Pages 109-115

  Tanaka, Yoichi ^a   Kato, Motohiro ^b   Hasegawa, Daisuke ^c   Urayama, Kevin Y ^d,e   Nakadate, Hisaya ^f   Kondoh, Kensuke ^g   Nakamura, Kozue ^h   Koh, Katsuyoshi ⁱ   Komiyama, Takako ^a   Manabe, Atsushi ^c  

^a KITASATO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e St Luke's Life Science Institute   (Japan)

^f NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h TEIKYO UNIVERSITY HOSPITAL   (Japan)

ⁱ SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

6 MP; Childhood acute lymphoblastic leukaemia; Japanese; NUDT15; Toxicities

Indexed keywords

MERCAPTOPURINE; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE; INORGANIC PYROPHOSPHATASE; MTH2 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; JAPANESE (PEOPLE); LEUKOPENIA; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NUDT15 GENE; PRIORITY JOURNAL; TREATMENT OUTCOME; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; INFANT; JAPAN; MORTALITY; MULTICENTER STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; TOXIC HEPATITIS;

6-MERCAPTOPURINE; ADOLESCENT; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; JAPAN; LEUKOPENIA; MALE; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYROPHOSPHATASES;

EID: 84941737589     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13518     Document Type: Article

References (20)

1. Kubota, T. & Chiba, K. (2001) Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. British Journal of Clinical Pharmacology, 51, 475-477.
2. Kumagai, K., Hiyama, K., Ishioka, S., Sato, H., Yamanishi, Y., McLeod, H.L., Konishi, F., Maeda, H. & Yamakido, M. (2001) Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics, 11, 275-278.
3. Lennard, L. & Lilleyman, J.S. (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. Journal of Clinical Oncology, 7, 1816-1823.
4. Manabe, A., Ohara, A., Hasegawa, D., Koh, K., Saito, T., Kiyokawa, N., Kikuchi, A., Takahashi, H., Ikuta, K., Hayashi, Y., Hanada, R. & Tsuchida, M. (2008) Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15. Haematologica, 93, 1155-1160.
5. Nygaard, U., Toft, N. & Schmiegelow, K. (2004) Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clinical Pharmacology and Therapeutics, 75, 274-281.
6. Relling, M.V. & Ramsey, L.B. (2013) Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematology/ the Education Program of the American Society of Hematology, 2013, 126-130.
7. Relling, M.V., Hancock, M.L., Boyett, J.M., Pui, C.H. & Evans, W.E. (1999a) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood, 93, 2817-2823.
8. Relling, M.V., Hancock, M.L., Rivera, G.K., Sandlund, J.T., Ribeiro, R.C., Krynetski, E.Y., Pui, C.H. & Evans, W.E. (1999b) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. Journal of the National Cancer Institute, 91, 2001-2008.
9. Schmiegelow, K. (1991) Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatric Hematology and Oncology, 8, 301-312.
10. Schmiegelow, K. & Pulczynska, M.K. (1990) Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? The American Journal of Pediatric Hematology/Oncology, 12, 462-467.
11. Schmiegelow, K., Bjork, O., Glomstein, A., Gustafsson, G., Keiding, N., Kristinsson, J., Makipernaa, A., Rosthoj, S., Szumlanski, C., Sorensen, T.M. & Weinshilboum, R. (2003) Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 21, 1332-1339.
12. Schmiegelow, K., Al-Modhwahi, I., Andersen, M.K., Behrendtz, M., Forestier, E., Hasle, H., Heyman, M., Kristinsson, J., Nersting, J., Nygaard, R., Svendsen, A.L., Vettenranta, K., Weinshilboum, R. & Nordic Society for Paediatric, H. & Oncology (2009) Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood, 113, 6077-6084.
13. Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze, G., Gadner, H., Odenwald, E. & Riehm, H. (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 Berlin-Frankfurt-Munster. Leukemia, 14, 2205-2222.
14. Stanulla, M., Schaeffeler, E., Moricke, A., Coulthard, S.A., Cario, G., Schrauder, A., Kaatsch, P., Dordelmann, M., Welte, K., Zimmermann, M., Reiter, A., Eichelbaum, M., Riehm, H., Schrappe, M. & Schwab, M. (2009) Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. Blood, 114, 1314-1318.
15. Takagi, Y., Setoyama, D., Ito, R., Kamiya, H., Yamagata, Y. & Sekiguchi, M. (2012) Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2. Journal of Biological Chemistry, 287, 21541-21549.
16. Tanaka, Y., Manabe, A., Nakadate, H., Kondoh, K., Nakamura, K., Koh, K., Utano, T., Kikuchi, A. & Komiyama, T. (2012) The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leukemia Research, 36, 560-564.
17. Tanaka, Y., Manabe, A., Fukushima, H., Suzuki, R., Nakadate, H., Kondoh, K., Nakamura, K., Koh, K. & Komiyama, T. (2014) Multidrug resistence protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maitenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics Journal, doi:10.1038/tpj.2014.74. In Press
18. Toyoda, Y., Manabe, A., Tsuchida, M., Hanada, R., Ikuta, K., Okimoto, Y., Ohara, A., Ohkawa, Y., Mori, T., Ishimoto, K., Sato, T., Kaneko, T., Maeda, M., Koike, K., Shitara, T., Hoshi, Y., Hosoya, R., Tsunematsu, Y., Bessho, F., Nakazawa, S. & Saito, T. (2000) Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. Journal of Clinical Oncology, 18, 1508-1516.
19. Yang, S.K., Hong, M., Baek, J., Choi, H., Zhao, W., Jung, Y., Haritunians, T., Ye, B.D., Kim, K.J., Park, S.H., Park, S.K., Yang, D.H., Dubinsky, M., Lee, I., McGovern, D.P., Liu, J. & Song, K. (2014) A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nature Genetics, 46, 1017-1020.
20. Yang, J.J., Landier, W., Yang, W., Liu, C., Hageman, L., Cheng, C., Pei, D., Chen, Y., Crews, K.R., Kornegay, N., Wong, F.L., Evans, W.E., Pui, C.H., Bhatia, S. & Relling, M.V. (2015) Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 33, 1235-1242.